The Effect of LSVT BIG Treatment on Motor and Nonmontor Symtoms in Patients with Parkinson's Disease

Status

Recruiting

Phases

Early Phase 1

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR2000029025

Enrollment

Unknown

Registered

2020-01-11

Start date

2020-01-13

Completion date

Unknown

Last updated

2020-01-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Parkinson's disease

Interventions

experimental group:LSVT BIG treatment

control group:Non-rehabilitation

Eligibility

Sex/Gender

All

Age

30 Years to 85 Years

Inclusion criteria

Inclusion criteria: (1)Willing to sign informed consent; (2)Diagnosed with primary Parkinson's disease:Hoehn & Yahr stages I–III; (3)Aged >= 30 years old, <85 years old; (4)Stable anti-parkinsonism medication at 1 month before study initiation and at the end of follow-up.

Exclusion criteria

Exclusion criteria: (1) Unable to conduct daily on/off periods self-report (3 consecutive days) (2)With untreated cancer, dementia (MMSE =29 points at screening), hypotension (blood pressure below 90/60 mm Hg); (3)Have a history of epilepsy, or have a history of stroke or transient cerebral ischemia within 1 year before screening; (4)With disabling dyskinesia and comorbidities that affect mobility or ability to exercise; (5)Patients with a history of pallioglobotomy, thalamic destruction, deep brain stimulation or fetal tissue transplantation (6)Participated in other sports for rehabilitation training within 3 months before screening (7)Cardiopulmonary function intolerance (New York Heart Association (NYHA) grade II or higher congestive heart failure, unstable angina, myocardial infarction, cardiovascular disease, or those with arrhythmia and lung diseases requiring treatment at screening); (8)Pregnant women; (9)Have other clinically significant medical conditions, mental conditions or laboratory abnormalities that may interfere with the subject's ability to participate in the study, as determined by the investigator.

Design outcomes

Primary

Measure	Time frame
the Unified Parkinson's Disease Rating Scale part III (UPDRS III) score;	—

Secondary

Measure	Time frame
PDQ-8 score;NMSS score;TUG score;BBT score;Beck-II score;UPDRS-I, II, IV score;	—

Countries

China

Contacts

Public ContactEnxiang Tao

Sun Yat-Sen Memorial Hospital, Sun Yat-Sen University

taoenxiang@163.com+86 18922182831

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026